Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF

Cancer Letters

Volumn 280, Issue 1, 2009, Pages 78-85

  Zou, Jia Ning ^a   Wang, Shu Zhen ^a   Yang, Jia Sen ^a   Luo, Xue Gang ^a   Xie, Jing Hang ^a   Xi, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

HGF c Met; Migration and invasion; RNA interference; SMYD3

Indexed keywords

HISTONE H3; PROTEIN SMYD3; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RNA INTERFERENCE; STOMACH CARCINOMA; TRANSACTIVATION; UPREGULATION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; HELA CELLS; HEPATOCYTE GROWTH FACTOR; HISTONE-LYSINE N-METHYLTRANSFERASE; HL-60 CELLS; HUMANS; K562 CELLS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE;

EID: 67349218722     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.015     Document Type: Article

References (38)

1. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
2. Goll M.D., and Bestor T.H. Histone modification and replacement in chromatin activation. Genes Dev. 16 (2002) 1739-1742
3. Berger S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12 (2002) 142-148
4. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
5. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
6. Sterner D.E., and Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64 (2000) 435-459
7. Nowak S.J., and Corces V.G. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 20 (2004) 214-220
8. Zhang Y., and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 15 (2006) 2343-2360
9. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75 (2006) 243-269
10. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Richard R.G.A.B., Otte A.P., Rubin M.A., and Arul A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
11. Gibbons R.J. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum. Mol. Genet. 14 (2005) R85-92
12. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., and Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6 (2004) 731-740
13. Hamamoto R., Silva F.P., Tsuge M., Katagiri T., Nakamura Y., and Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97 (2006) 113-118
14. Kunizaki M., Hamamoto R., Silva F.P., Yamaguchi K., Nagayasu T., Shibuya M., Nakamura Y., and Furukawa Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 67 (2007) 10759-10765
15. Luo X.G., Lin C., Lu Y.H., Zhou Q.F., and Xi T. Correlation between SMYD3 and cell proliferation and its effect on cell cycle. J. China Pharmaceut. University 38 (2007) 277-282
16. Luo X.G., Yan D., Zhou Q.F., Ye L., and Xi T. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 Cells. J. Biosci. Bioeng. 103 (2007) 444-450
17. Wang S.Z., Luo X.G., Shen J., Zou J.N., Lu Y.H., and Xi T. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cells growth and invasion in vitro. BMB. Rep. 41 (2008) 294-299
18. Wang S.Z., Luo X.G., Yan D., Shen J., Lu Y.H., and Xi T. Suppression of SMYD3 expression in HeLa cells by an inducible shRNAs expression system. J. China Pharmaceut. University 38 (2007) 369-374
19. Liu C., Fang X., Ge Z., Jalink M., Kyo S., Bjorkholm M., Gruber A., Sjoberg J., and Xu D. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res. 67 (2007) 2626-2631
20. Marc M., and Ancy L. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 83 (2003) 337-376
21. Zhao Z.C., Zheng S.S., Wan Y.L., Jia C.K., and Xie H.Y. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. HBPD. Int. 2 (2003) 529-536
22. Bartek J., and Lukas J. Are all cancer genes equal?. Nature 411 (2001) 1001-1002
23. Zajchowski D.A., Bartholdi M.F., Gong Y., Webster L., Liu H.L., Munishkin A., Beauheim C., Harvey S., Ethier S.P., and Johnson P.H. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 61 (2001) 5168-5178
24. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande G.F., and Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 (1991) 802-804
25. Voort R.V.D., Taher T.E.I., Derksen P.W.B., Spaargaren M., Neut R.V.D., and Pals S.T. The hepatocyte growth factor-Met pathway in development, tumorigenesis, and B cell differentiation. Adv. Cancer Res. 79 (2000) 39-90
26. Parr C., and Jiang W.G. Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Histol. Histopathol. 16 (2001) 251-268
27. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K., and Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol./Hematol. 53 (2005) 35-69
28. Birchmeier C., Birchmeier W., Gherardi E., and Woude G.F.V. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
29. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., and Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13 (2002) 41-59
30. Royal I., Lamarche-Vane N., Lamorte L., Kaibuchi K., and Park M. Activation of Cdc42, Rac, PAK, and Rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell 11 (2000) 1709-1725
31. Trusolino L., and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 13 (2002) 289-300
32. Knudsen B.S., and Woude G.V. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18 (2008) 87-96
33. Galperin M.Y. The molecular biology database collection: 2005 update. Nucleic Acids Res. 33 (2005) D5-D24
34. Gambarotto G., Pistoi S., Giordano S., Comolio P.M., and Santoro C. Structure and inducible regulation of the human MET promoter. J. Biol. Chem. 269 (1994) 12852-12857
35. Keleg S., Buchler P., Ludwig R., Buchler M.W., and Friess H. Invasion and metastasis in pancreatic cancer. Mol. Cancer 2 (2003) 14-21
36. Tan X., Rotllant J., Li H., Dedeyne P., and Du S.J. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc. Natl. Acad. Sci. 103 (2006) 2713-2718
37. Brown M.A., Sims R.J., Gottlieb P.D., and Tucker P.W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 28 (2006) 26-37
38. Thompson E.C., and Travers A.A. A Drosophila Smyd4 homologue is a muscle-specific transcriptional modulator involved in development. PLoS ONE 3 (2008) e3008